Replies to post #93822 on Biotech Values

[DewDiligence]

Good survey idea, but I will modify the answer choices to the second question. If the FDA approves multiple generics, it’s a near certainty that SNY will launch an AG, so we don’t need an answer choice for the case with multiple approvals and no AG. Also, I think there should be an answer choice for simultaneous FDA approvals for NVS/MNTA and TEVA.